David Einhorn’s Greenlight Capital bought a “small long position” in Roivant Sciences during Q1, according to its quarterly letter to shareholders
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ROIV:
- Cantor Fitzgerald biopharma analyst holds analyst/industry conference call
- Moderna could owe $1B-$3B in royalties, says Jefferies
- Roivant, Arbutus higher after ruling on COVID patent order
- Jefferies sees Roivant rallying 5%-10% on today’s COVID patent order
- Roivant Sciences price target raised to $18 from $17 at H.C. Wainwright